8-K: Xilio Therapeutics Reports Q2 2025 Results, Pipeline Progress

Xilio Therapeutics announced its second quarter 2025 financial results and pipeline updates, highlighting positive Phase 2 vilastobart data and a strengthened cash position.

Summary

• Second quarter 2025 financial results and business highlights were announced.
• Updated Phase 2 data for vilastobart (tumor-activated, Fc-enhanced, anti-CTLA-4) was presented at ASCO, demonstrating a preliminary 26% objective response rate in heavily pre-treated metastatic MSS CRC patients without liver metastases, with deep and durable responses and a differentiated, well-tolerated safety profile.
• The company is on track to nominate its first development candidates for wholly owned masked T cell engager programs in the second half of 2025.
• Cash and cash equivalents totaled $121.6 million as of June 30, 2025, with an anticipated cash runway through the end of the third quarter of 2026.
• Enrollment in Phase 1A monotherapy dose escalation for XTX301 (tumor-activated IL-12) has been completed, and Phase 1B monotherapy dose expansion is ongoing.
• XTX501 (masked PD-1/IL-2 bispecific) is advancing in IND-enabling studies, with an IND application planned for the middle of 2026.
• A follow-on public offering closed in June 2025, generating approximately $50.0 million in initial gross proceeds, with potential for up to $100.0 million more from warrant exercises by the second half of 2026.
• Akintunde (Tunde) Bello, Ph.D., was appointed to the company's board of directors in June 2025.

Sentiment

Score: 7

Explanation: The company reported an increased net loss and higher expenses, which are negative. However, these are offset by a significantly strengthened cash position, extended cash runway, positive clinical data for vilastobart, and continued pipeline progress with multiple programs advancing and new development candidates expected. The clinical validation of their masking technology and strategic partnerships are strong positives for a clinical-stage biotech.

Positives

• Cash and cash equivalents significantly increased to $121.6 million as of June 30, 2025, up from $55.3 million as of December 31, 2024.
• Anticipated cash runway extended through the end of the third quarter of 2026, providing financial stability.
• Promising updated Phase 2 data for vilastobart showed a preliminary 26% objective response rate in heavily pre-treated metastatic MSS CRC patients without liver metastases, including deep and durable responses.
• Vilastobart demonstrated a differentiated and well-tolerated safety profile with a low incidence of colitis and other immune-related adverse events, validating the company's proprietary masking technology.
• Collaboration and license revenue increased to $8.1 million for Q2 2025, up from $2.4 million for Q2 2024, driven by collaborations with AbbVie and Gilead.
• Continued progress across the pipeline with XTX301 advancing in Phase 1B dose expansion and XTX501 in IND-enabling studies.
• Successful follow-on public offering raised initial $50.0 million, with potential for an additional $100.0 million from warrant exercises.

Negatives

• Net loss increased to $15.8 million for the quarter ended June 30, 2025, compared to $13.9 million for the same period in 2024.
• Research & Development (R&D) expenses increased to $15.3 million for Q2 2025 from $11.2 million for Q2 2024, primarily due to increased clinical development activities for vilastobart, early-stage programs, and personnel-related costs.
• General & Administrative (G&A) expenses increased to $7.1 million for Q2 2025 from $5.8 million for Q2 2024, mainly due to higher professional and consulting fees and personnel-related costs.

Risks

• General market conditions and geopolitical uncertainties.
• Risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials.
• The delay of any current or planned preclinical studies or clinical trials or the development of product candidates.
• Ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates.
• Ability to advance multiple early stage masked T cell engager programs.
• Initial, preliminary or interim preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain approval on a timely basis, if at all.
• Results from preclinical studies or clinical trials for product candidates may not support further development.
• Actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials.
• Ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates.
• Need to obtain additional cash resources to advance the pipeline of tumor-activated I-O molecules.
• Impact of international trade policies on business, including U.S. and China trade policies.
• Ability to maintain collaboration or partnership agreements with AbbVie, Gilead and Roche.

Future Outlook

Xilio anticipates its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements through the end of the third quarter of 2026. The company plans to nominate its first development candidates for wholly owned masked T cell engager programs in the second half of 2025, submit an IND application for XTX501 in the middle of 2026, and advance at least two masked T cell engager programs into initial IND-enabling studies with IND applications in 2027. Additional Phase 2 data for vilastobart is expected in the first half of 2026.

Management Comments

• "During the second quarter, we continued to make strong progress across our pipeline of novel tumor-activated immuno-oncology therapies, and with our recent financing, we believe that we are well-positioned to execute on our strategic goals."
• "We believe our masked T cell engager molecules have the potential to be best-in-class, and we anticipate nominating our first development candidates for our wholly owned programs later this year."
• "In addition, we are very encouraged by the clinical progress for XTX301, our tumor-activated IL-12 advancing in partnership with Gilead, and we look forward to providing a program update in the near-term."
• "We also recently reported updated Phase 2 combination data for vilastobart at ASCO and believe these data not only highlight the significant opportunity for vilastobart across a range of I-O combinations and tumor types, but also provide further clinical validation for our proprietary masking technology and approach."

Industry Context

Xilio Therapeutics operates in the highly competitive immuno-oncology sector, focusing on developing tumor-activated therapies to mitigate systemic side effects common with current treatments. The positive Phase 2 data for vilastobart, an anti-CTLA-4, is particularly significant given the historical challenges of toxicity associated with this drug class. This suggests a potentially differentiated safety profile that could position vilastobart favorably in the market. The company's strategic focus on masked T cell engagers and IL-12 aligns with broader industry trends towards more targeted and potent immunotherapies for 'cold' tumors. Furthermore, collaborations with major pharmaceutical companies like Gilead and AbbVie provide external validation of Xilio's proprietary platform and pipeline assets.

Comparison to Industry Standards

• The 26% objective response rate for vilastobart in heavily pre-treated metastatic MSS CRC patients without liver metastases, coupled with a 'differentiated and well-tolerated safety profile with a low incidence of colitis and other immune-related adverse events,' is a notable achievement. This compares favorably to traditional anti-CTLA-4 therapies (e.g., ipilimumab), which often face limitations due to higher rates of immune-related adverse events, particularly colitis, impacting their broader use or combination potential.
• The clinical validation of Xilio's proprietary masking technology through vilastobart's profile addresses a critical industry challenge: improving the therapeutic index of immuno-oncology therapies by localizing anti-tumor activity within the tumor microenvironment, thereby reducing systemic toxicity.
• The ongoing collaborations with Gilead for XTX301 (IL-12) and AbbVie for masked T cell engagers demonstrate external validation of Xilio's platform, reflecting a common industry trend where larger pharmaceutical companies partner with innovative biotech firms for promising early-stage assets to expand their oncology pipelines.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from extended cash runway and potential for future warrant exercises, which de-risks near-term liquidity. Positive clinical data could enhance company valuation. Negative impact from increased net loss.
• Employees: Increased R&D and G&A expenses include increased personnel-related costs, suggesting stable or growing employment opportunities.
• Customers (Patients): Potential for new, more tolerable cancer therapies if pipeline candidates successfully advance through clinical development and gain approval.
• Partners (Gilead, AbbVie, Roche): Continued collaboration and progress on partnered programs reinforce the value of these strategic alliances.

Next Steps

• Nominate first development candidates for wholly owned masked T cell engager programs in the second half of 2025.
• Provide a program update for XTX301 in the near-term.
• Report additional data from the Phase 2 trial for vilastobart in the first half of 2026.
• Submit an IND application for XTX501 in the middle of 2026.
• Nominate development candidate for PSMA program (ATACR format) in Q3 2025.
• Nominate development candidate for CLDN18.2 program (ATACR format) in Q4 2025.
• Nominate development candidate for STEAP1 program (SEECR format) in H1 2026.
• Advance at least two masked T cell engager programs into initial IND-enabling studies and submit IND applications in 2027.
• Engage strategic partners on potential opportunities to accelerate and expand further development for vilastobart.

Key Dates

Recommendation

While the company reported an increased net loss and higher operating expenses, these are typical for a clinical-stage biotechnology company advancing multiple programs. The significant cash infusion from the recent offering, extending the cash runway through Q3 2026, substantially de-risks near-term liquidity concerns. The positive Phase 2 data for vilastobart, particularly its differentiated safety profile, provides strong clinical validation for Xilio's masking technology and suggests significant therapeutic potential, which could attract further partnerships. The advancement of multiple preclinical and clinical programs, including the nomination of new development candidates, indicates a robust pipeline. However, the company is still in early to mid-stage clinical development, and future success is highly dependent on further positive clinical trial results and regulatory approvals, which carry inherent risks. Given the mix of strong clinical progress and financial stability improvements against the backdrop of increased losses and early-stage pipeline, a 'hold' recommendation is appropriate for investors to monitor further clinical milestones and financial performance.

Keywords

Biotechnology, Immuno-oncology, Cancer therapy, Clinical trials, Drug development, SEC filing, Xilio Therapeutics, Vilastobart, XTX301, XTX501, CTLA-4, IL-12, PD-1/IL-2, T cell engagers, Oncology, Biopharma, NASDAQ: XLO